Vadodara News Flash

Surgical Site Infection Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies Botanix Pharma, Destiny Pharama

 Breaking News
  • No posts were found

Surgical Site Infection Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies Botanix Pharma, Destiny Pharama

September 14
09:14 2023
Surgical Site Infection  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies Botanix Pharma, Destiny Pharama
DelveInsight Business Research LLP
DelveInsight’s “Surgical Site Infections (SSI) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Surgical Site Infections (SSI), historical and forecasted epidemiology as well as the Surgical Site Infections (SSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s Surgical Site Infections (SSI) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Surgical Site Infections (SSI), historical and forecasted epidemiology as well as the Surgical Site Infections (SSI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights Surgical Site Infection Market 

  • Key Companies working in the Surgical Site Infection market are Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, and many others 

  • Key Therapies in Surgical Site Infection are Chlorhexidine Gluconate, Mupirocin, Cefazolin, and many others.

  • The market size for the Surgical Site Infection market is USD XX Million by 2032 

  • The CAGR for the Surgical Site Infection market is XX%

Surgical Site Infection Overview

Surgical Infections is a peer-reviewed published  It is the official journal of the Surgical Infection Society, the Surgical Infection Society Europe, the Surgical Infection Society Latin America, and the Chinese Society of Surgical Infection and Intensive Care. Surgical Infections “provides information on the biology, prevention, and management of post-operative infections. 

Surgical Site Infection Epidemiology Insights

  • The incidence of SSIs may be as high as 20%, depending on the surgical procedure, the surveillance criteria used, and the quality of data collection. In many SSIs, the responsible pathogens originate from the patient’s endogenous flora.

  • These infections number approximately 500,000 per year, among an estimated 27 million surgical procedures, and account for approximately one-quarter of the estimated 2 million nosocomial infections in the United States each year (3). Infections result in longer hospitalization and higher costs.

 

The Report Covers the Surgical Site Infection  Epidemiology Segmented by:

  • Surgical Site Infection prevalent cases  

  • Surgical Site Infection incident cases 

  • Surgical Site Infection treatment cases 

  • Surgical Site Infection diagnosed cases 

Surgical Site Infection Market Outlook 

The Surgical Site Infections (SSI) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Surgical Site Infections (SSI) market trends by analyzing the impact of current Surgical Site Infections (SSI) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Surgical Site Infections (SSI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Surgical Site Infections (SSI) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Surgical Site Infections (SSI) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Surgical Site Infection Market

  • Destiny Pharma

  • PolyPid

  • Menarini Group Pharma

  • Botanix Pharma

  • Dr. Reddy’s Laboratories Ltd.

  • Zurex Pharma

And many others

 

Surgical Site Infection Therapies Covered and Analyzed in the Report

  • Ampicillin 

  • Cephaloridine

And many others 

Learn more about the Key Companies and Emerging Therapies in the Surgical Site Infection Market

 

Table of Contents 

  1.  Key Insights 

  2.  Surgical Site Infection Introduction 

  3.  Executive Summary of Surgical Site Infection           

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Surgical Site Infection  Emerging Therapies

  7.  Surgical Site Infection  Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Surgical Site Infection Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Related Articles